June 17th 2024
Your daily dose of the clinical news you may have missed.
June 13th 2024
More than 50% of patients with MASH receiving 1 of 3 doses of tirzepatide achieved MASH resolution without worsening of fibrosis vs placebo, according to data from phase 2 study.
June 11th 2024
June 4th 2024
ENDO 2024. New findings suggest GLP-1RAs and SGLT-2is may be more beneficial than other diabetes agents for patients with T2D and MASLD.
May 24th 2024
Children of Parents with Obesity or Overweight Face Increased Risk of MASLD Later in Life
DDW 2024. Offspring with both parents with overweight had a nearly 3-fold increased risk of MASLD in young adulthood, according to new data.
GLP-1 Agonists Reduce Risk of Cirrhosis, HCC in Adults with MASLD and T2D
DDW 24. New research shows patients with MASLD and T2D who used GLP-1 agonists had a reduced risk of progression to cirrhosis and HCC vs non-users.
The Pipeline for New MASLD & MASH Treatments is Promising, says Naim Alkhouri, MD
Following the landmark FDA approval of resmetirom for MASH with fibrosis, hepatologist and researcher Alkhouri describes more mid- and late-stage candidates.
A MASLD Mantra to Practice By: Screen, Stage, Treat
Hepatologist Naim Alkhouri, MD, offered 3 take-home thoughts for primary care colleagues to help increase early detection of MASLD.
The FDA Approval of Resmetirom for MASH Changes Everything—for Patients and their Physicians
Naim Alkhouri, MD, a transplant hepatologist and a resmetirom investigator, talks here about the life-changing impact the drug will have for all touched by MASH.
Early Detection of MASLD in Primary Care: The Essentials with Naim Alkhouri, MD
Primary care is where early detection and treatment of liver disease should begin and as Dr Alkhouri highlights here, all the right tools are already at hand.
American Liver Foundation Announces First Federally-Funded Research on MASLD
The national study on the true prevalence of metabolic dysfunction-associated liver disease is essential to screening, prevention, and treatment efforts, says AFL CEO Stiehl.
The Rate of Undetected MASLD in the US is a Sobering Statistic, says Expert Hepatologist Naim Alkhouri, MD
Alkhouri, a veteran investigator in the field of hepatic disease, including MASLD and MASH, stresses the need for early detection of MASLD when simple intervention can be effective.
Madrigal Announces US Availability of Resmetirom (Rezdiffra), First Patients Treated for NASH
Resmetirom to treat NASH with F2-F3 fibrosis, the only approved therapy, is available through Madrigal's specialty pharmacy network, the company said.
Lanifibranor Plus Empagliflozin Effective in T2D, MASH: Proof-of-Concept Ph2 Findings
LEGEND phase 2 interim analysis findings include significant decreases in HbA1c in poorly controlled T2D and positive effects on several markers of liver injury.
Underrepresentation of Patients with CKD in CVD Medication Trials: Daily Dose
Madrigal's Resmetirom Wins Historic FDA Approval for Noncirrhotic NASH
Resmetirom is the first-ever drug to be approved anywhere for management of the progressive liver disease.
Antisense Molecule against MASH from Ionis Meets Primary Endpoint in Phase 2 Trial
Ionis reports the first clinical evidence that DGAT2 inhibition-driven reduction of hepatic fat correlates with improvements in MASH histologic endpoints.
Pegazofermin Enters Phase 3 ENLIGHTEN Clinical Trial Program for MASH
The 2 phase 3 trials in the 89bio ENLIGHTEN clinical trial program will evaluate the safety and efficacy of the FGF21 analog in MASH, fibrosis.
Underrepresentation of Individuals with CKD in CV Medication Trials Found Persistent Over 2 Decades
Authors: Exclusion of people with CKD from CV medication trials has left significant gaps in understanding the effectiveness of these drugs in a highly vulnerable population.
Resmetirom for NASH: MASESTRO-NASH Phase 3 Data in NEJM Precede PDUFA Date of 3-14-2024
Resmetirom vs placebo led to significantly greater proportion of adults reaching NASH resolution without increased fibrosis and with fibrosis improvement by ≥1 stage.
Survodutide, Dual Glucagon/GLP-1 Mimetic, Improves MASH in 83% of Phase 2 Trial Participants
The statistically significant improvements in MASH with survodutide were seen without worsening fibrosis and included a relative reduction of steatosis of 30%.
SGLT2 Inhibitors Outperformed Other Oral Antidiabetic Drugs for Persons with T2D, NAFLD: Daily Dose
SGLT2 Inhibitors Outperformed Other Oral Antidiabetic Drugs for Patients with T2D and NAFLD, According to New Research
Findings suggest that SGLT2 inhibitors may be the preferred choice for patients with both T2D and NAFLD, reported researchers.
Noninvasive Tests May be Poor Predictor of Liver Fibrosis, Especially Among Black Adults
Using FIB-4 index first to screen for cirrhosis may lead to clinicians missing 48% of cases, according to a recent study.
Alcohol-Related Liver Disease May be More Deadly Among Women than Men, Study Suggests
Risk of mortality from ALD and MetALD was significantly higher among women even though both phenotypes were more prevalent among men, a new study reveals.
Daily Dose: Lack of Osteoporosis Screening, Treatment in Patients with Cirrhosis
Daily Dose: NAFLD Associated with Adverse Outcomes Regardless of BMI
Fibrosis Screening Results May Motivate Behavior Change in Adults at Risk of Liver Disease: Danish Study
Screening for fibrosis in persons at risk of ALD and MASLD led to sustained improvements in lifestyle, eg, reduced alcohol consumption, weight loss, and increased exercise.
Screening and Treatment for Osteoporosis Lacking for Persons with Cirrhosis, According to Real-World Analysis
Less than a quarter of persons with cirrhosis who are diagnosed with osteoporosis are started on treatment, reported researchers.
ACG Releases New Clinical Guideline for Management of Alcohol-Associated Liver Disease
The new guideline underscores the need to overcome barriers to alcohol use disorder treatment and expand multidisciplinary care for patients with ALD.
NAFLD Linked to Adverse Outcomes Regardless of BMI, New Research Suggests
Individuals with "lean NAFLD" may be at similar risk of NASH, cirrhosis, nonliver cancer, and death as as those with NAFLD and overweight or obesity, authors say.
Program Buoys Hope for Eradication of HCV
More Timely Care for Chronic Liver Disease is Coming, Step-by-Step, says Hepatologist Bruce Luxon, MD, PhD
Reducing stigma associated with chronic liver disease and expediting diagnosis and referral will take some time but progress is being made, Luxon says.
To Help Reduce the Burden of Chronic Liver Disease, Primary Care Needs Simple, Reliable, Available Tools
Transplant hepatologist Dr Bruce Luxon says primary care is essential to making progress against chronic liver disease but doesn't have the resources it needs.